In this cohort, biallelic CHEK2 PV carriers had a significantly higher risk for breast cancer, were more likely to be diagnosed at or before age 50, and were more likely to have multiple primary breast cancers compared to monoallelic CHEK2 PV carriers. This evidence concerns the gene CHEK2 and breast carcinoma.